PIM1 kinase is essential for the growth of MYC-overexpressing triple-negative breast tumors and is an efficacious therapeutic target

Autor: Horiuchi, D, Zhou, AY, Corella, AN, Yau, C, Lawson, DA, Bazarov, AV, Yaswen, P, McManus, MT, Welm, AL, Werb, Z, Goga, A

Publikováno v: MOLECULAR CANCER THERAPEUTICS, vol 12, iss 11
Horiuchi, D; Zhou, AY; Corella, AN; Yau, C; Lawson, DA; Bazarov, AV; et al.(2013). PIM1 kinase is essential for the growth of MYC-overexpressing triple-negative breast tumors and is an efficacious therapeutic target. MOLECULAR CANCER THERAPEUTICS, 12(11). doi: 10.1158/1535-7163.TARG-13-B232. UCSF: Retrieved from: http://www.escholarship.org/uc/item/1pt500ts

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::3ba0f7b2682f836d409d862aaa564c3b
https://escholarship.org/uc/item/1pt500ts

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

PIM1 kinase inhibition as a targeted therapy against triple-negative breast tumors with elevated MYC expression.

Autor: Horiuchi D; Department of Cell and Tissue Biology, University of California, San Francisco (UCSF), San Francisco, California, USA.; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California, USA.; Department of Pharmacology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.; Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, USA., Camarda R; Department of Cell and Tissue Biology, University of California, San Francisco (UCSF), San Francisco, California, USA., Zhou AY; Department of Cell and Tissue Biology, University of California, San Francisco (UCSF), San Francisco, California, USA., Yau C; Department of Surgery, University of California, San Francisco, San Francisco, California, USA.; Cancer and Developmental Therapeutics Program, Buck Institute for Research on Aging, Novato, California, USA., Momcilovic O; Department of Cell and Tissue Biology, University of California, San Francisco (UCSF), San Francisco, California, USA., Balakrishnan S; Department of Cell and Tissue Biology, University of California, San Francisco (UCSF), San Francisco, California, USA., Corella AN; Department of Cell and Tissue Biology, University of California, San Francisco (UCSF), San Francisco, California, USA., Eyob H; Department of Cell and Tissue Biology, University of California, San Francisco (UCSF), San Francisco, California, USA., Kessenbrock K; Department of Anatomy, University of California, San Francisco, San Francisco, California, USA., Lawson DA; Department of Anatomy, University of California, San Francisco, San Francisco, California, USA., Marsh LA; Department of Pharmacology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.; Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, USA., Anderton BN; Department of Cell and Tissue Biology, University of California, San Francisco (UCSF), San Francisco, California, USA., Rohrberg J; Department of Cell and Tissue Biology, University of California, San Francisco (UCSF), San Francisco, California, USA., Kunder R; Department of Pharmacology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.; Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, USA., Bazarov AV; Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, California, USA., Yaswen P; Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, California, USA., McManus MT; Department of Microbiology and Immunology, University of California, San Francisco, San Francisco, California, USA., Rugo HS; Department of Medicine, University of California, San Francisco, San Francisco, California, USA., Werb Z; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California, USA.; Department of Anatomy, University of California, San Francisco, San Francisco, California, USA., Goga A; Department of Cell and Tissue Biology, University of California, San Francisco (UCSF), San Francisco, California, USA.; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California, USA.; Department of Medicine, University of California, San Francisco, San Francisco, California, USA.

Publikováno v: Nature medicine [Nat Med] 2016 Nov; Vol. 22 (11), pp. 1321-1329. Date of Electronic Publication: 2016 Oct 24.

The specific role of pRb in p16 (INK4A) -mediated arrest of normal and malignant human breast cells.

Autor: Bazarov AV; Department of Medicine, University of California at San Francisco, San Francisco, CA, USA., Lee WJ, Bazarov I, Bosire M, Hines WC, Stankovich B, Chicas A, Lowe SW, Yaswen P

Publikováno v: Cell cycle (Georgetown, Tex.) [Cell Cycle] 2012 Mar 01; Vol. 11 (5), pp. 1008-13. Date of Electronic Publication: 2012 Mar 01.

Who is in the driver's seat in 8p12 amplifications? ZNF703 in luminal B breast tumors.

Autor: Bazarov AV; Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, 94143, USA., Yaswen P

Publikováno v: Breast cancer research : BCR [Breast Cancer Res] 2011 May 25; Vol. 13 (3), pp. 308. Date of Electronic Publication: 2011 May 25.